The EMA’s Committee for Medicinal Products for Human Use issued positive recommendations for six different drugs.
Two of the treatments — Epclusa and Zepatier — are new hepatitis C combination treatments sponsored by Gilead and Merck, respectively.
British drug giant AstraZeneca also snagged the thumbs up from the committee for its Type 2 diabetes treatment Qtern.
The other three positive opinions covered generic medications: Hospira’s bortezomib and Sun’s version of bortezomib for the treatment of multiple myeloma and mantle cell lymphoma, and pemetrexed from Fresenius Kabi for the treatment of unresectable malignant pleural mesothelioma and metastatic non-small cell lung cancer.
Takeda Pharmaceuticals did not fare as well, with the committee giving a negative assessment for its multiple myeloma treatment Ninlaro. According to the committee, data from the main study did not demonstrate sufficient efficacy.